RareSearch logo

BioLamina

50+ personnel
Headquartered in Chandler
Established in 2025
Website
Misty Stark profile

Misty Stark

πŸ‡ΊπŸ‡Έ United States

9

    Reviewed:

  • - Clinical Protocol Design
  • - 6 weeks April - May 2023
  • - Pharmaceutical Company

Comprehensive protocol design, very detailed and precise.

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Nellie Tillman PhD profile

Nellie Tillman PhD

πŸ‡©πŸ‡ͺ Germany

8.6

    Reviewed:

  • - Patient Engagement
  • - 8 weeks August - September 2023
  • - Clinical Research Organization

Impressive patient engagement strategies, significant improvement in recruitment rates.

The patient engagement strategies implemented were impressive and led to a significant improvement in our recruitment rates. The team's experience in patient-centered approaches was evident and made a real difference.

Orville Osinski profile

Orville Osinski

πŸ‡³πŸ‡± Netherlands

9.1

    Reviewed:

  • - Pharmacovigilance Services
  • - Ongoing
  • - Pharmaceutical Company

Highly effective pharmacovigilance services, ensured compliance.

The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.

Earl Zemlak profile

Earl Zemlak

πŸ‡ΈπŸ‡¦ Saudi Arabia

9.3

    Reviewed:

  • - Project Management
  • - 10 weeks July - September 2023
  • - Biotech Company

Seamless project management, results exceeded expectations.

Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.

Edmund Dooley profile

Edmund Dooley

πŸ‡¨πŸ‡¦ Canada

6

    Reviewed:

  • - Health Technology Assessment
  • - 8 weeks July - September 2024
  • - Pharmaceutical Company

Health technology assessment was superficial, lacked thorough analysis.

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.